TY - JOUR
T1 - MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients
AU - Varmazyar, Sajad
AU - Marashi, Sayed Mahdi
AU - Shoja, Zabihollah
AU - Tornesello, Maria Lina
AU - Buonaguro, Franco M.
AU - Shahmahmoodi, Shohreh
AU - Safaie-Naraghi, Zahra
AU - Jalilvand, Somayeh
PY - 2017/4/1
Y1 - 2017/4/1
N2 - A single-nucleotide polymorphism (SNP) in the promoter region of MDM2 (SNP309T>G, rs2279744) has been shown to increase the expression of the MDM2 protein in various cancer types. However, only one study has analyzed the role of the MDM2 polymorphism in the development of Kaposi’s sarcoma (KS). The association of MDM2 SNP309 with classic KS risk was evaluated in 79 Iranian patients with classic KS and 123 healthy controls. The MDM2 SNP309 was genotyped using PCR and restriction fragment length polymorphism methods. No significant correlation was found between the SNP309 polymorphism in MDM2 promoter and classic KS risk. There was no significant correlation between gender and disease stage. However, a significant association was found between SNP309 GG genotype and younger age (≤50 years) (odds ratio 9.5, 95% confidence intervals 1.5–60, p = 0.03). Our findings support no major role for the MDM2 SNP309 in KS development although it might influence the clinical outcome of KS in younger patients.
AB - A single-nucleotide polymorphism (SNP) in the promoter region of MDM2 (SNP309T>G, rs2279744) has been shown to increase the expression of the MDM2 protein in various cancer types. However, only one study has analyzed the role of the MDM2 polymorphism in the development of Kaposi’s sarcoma (KS). The association of MDM2 SNP309 with classic KS risk was evaluated in 79 Iranian patients with classic KS and 123 healthy controls. The MDM2 SNP309 was genotyped using PCR and restriction fragment length polymorphism methods. No significant correlation was found between the SNP309 polymorphism in MDM2 promoter and classic KS risk. There was no significant correlation between gender and disease stage. However, a significant association was found between SNP309 GG genotype and younger age (≤50 years) (odds ratio 9.5, 95% confidence intervals 1.5–60, p = 0.03). Our findings support no major role for the MDM2 SNP309 in KS development although it might influence the clinical outcome of KS in younger patients.
KW - Kaposi’s sarcoma
KW - MDM2
KW - Risk factor
KW - Single-nucleotide polymorphism
UR - http://www.scopus.com/inward/record.url?scp=85009291876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009291876&partnerID=8YFLogxK
U2 - 10.1007/s00430-016-0491-9
DO - 10.1007/s00430-016-0491-9
M3 - Article
C2 - 28083704
AN - SCOPUS:85009291876
VL - 206
SP - 157
EP - 163
JO - Medical Microbiology and Immunology
JF - Medical Microbiology and Immunology
SN - 0300-8584
IS - 2
ER -